logo
Argentines reel from health care cutbacks as President Milei's state overhaul mirrors Trump's

Argentines reel from health care cutbacks as President Milei's state overhaul mirrors Trump's

BUENOS AIRES, Argentina (AP) — To outsiders, the Facebook group chat reads like a snarl of nonsensical emojis and letters. To uninsured Argentine cancer patients, it's a lifeline.
The surreptitious network connects advocates who have spare drugs to Argentines with cancer who lost access to their treatment in March 2024 when President Javier Milei suspended a federal agency, known as DADSE, that paid for their expensive medications.
Whenever Facebook cracks the coded pleas and removes the group for violating its rules on drug sales, another appears, swelling with Argentines who say they've grown sicker since the radical libertarian president took a chainsaw to health care.
'All I need for my body to function is this medication, and Milei is saying, 'There's no money,'' said Ariel Wagener, a 47-year-old pizza chef with leukemia who was hospitalized this year with failing kidneys after losing access to his medication. Without DADSE, a month's worth of his leukemia drug costs $21,000.
Wagener's condition stabilized after he got leftover medication via Facebook, donated by a family whose loved one had died of cancer.
The halting of millions of dollars of free cancer drugs is just one way Milei's austerity drive has torn through the public health system that once set Argentina apart in Latin America, ensuring that health care was free for pretty much everyone who couldn't afford private insurance.
Since taking office in December 2023, Milei has slashed Argentina's health care budget by 48% in real terms. His administration fired over 2,000 Health Ministry employees, including 1,400 over just a few days in January.
As part of Milei's plan to remake Argentina's troubled economy and cut waste and bureaucracy, officials gutted the National Cancer Institute, suspending early detection programs for breast and cervical cancer.
They froze federal funds for immunization campaigns, hobbling vaccine access as Argentina confronts a measles outbreak for the first time in decades. They dismantled the National Directorate for HIV, Hepatitis and Tuberculosis, leading to testing and treatment delays. They defunded emergency contraception and stopped distributing abortion pills.
'We're seeing setbacks we haven't seen in decades,' said María Fernanda Boriotti, president of Argentina's Federation of Health Professionals. 'HIV patients without treatment, cancer patients dying for lack of medication, hospitals without resources, health professionals pushed out of the system.'
The government curtailed medical coverage for retirees and lifted price controls on prescription medication and private health plans, causing prices to spike by 250% and 118% respectively, official data shows.
'We've stopped buying milk, yogurt, anything that's not absolutely essential,' said Susana Pecora, 71, who lost the insurance plan that covered her husband's antipsychotic drugs when the price jumped 40% last year.
Milei and Trump see eye-to-eye
Milei campaigned on a promise to shrink the state two years before President Donald Trump and Elon Musk took up their own chainsaws.
The Argentine has become a close ally of the Trump administration, including on health policy. Argentina has followed the U.S. out of the World Health Organization, and last month received a visit from U.S. Secretary of Health and Human Services Robert F. Kennedy Jr.
Meeting Kennedy in Buenos Aires, Argentine Health Minister Mario Lugones announced a review of Argentina's health system to align it with Kennedy's Make America Healthy Again movement.
'We have similar visions about the path forward,' Lugones said of Kennedy.
Milei has not yet attempted to replace universal coverage with an insurance-based system, as he vowed on the campaign trail.
But in stripping Argentines of coverage and increasing premiums and out-of-pocket expenses, he is moving Argentina closer to the U.S. model, said Macarena Sabin Paz, health team coordinator at Argentina's Center for Legal and Social Studies.
'We are beginning to see the idea ... where if you lose your job, or become seriously ill, you may have to sell your car, whatever you have, to pay for health care,' she said.
Milei's staffing cuts have eviscerated agencies tasked with planning, financing and tracking immunization campaigns, disrupting data collection and jeopardizing the country's respected childhood vaccine program.
The cuts have coincided with a measles outbreak that in April led to Argentina's first measles death in two decades.
'Argentina has been one of the most advanced South American countries and here we see it abandoning public health,' said Dr. Stanley Plotkin, an American physician who helped develop the measles vaccine in the 1960s.
Milei's spokesperson, Manuel Adorni, did not respond to requests for comment. Lugones also did not respond to questions on the impact of policy changes.
A tidal wave of cuts After decades of unbridled spending by left-wing populist governments that brought Argentina infamy for defaulting on its debts, Milei delivered on his campaign promises of taming extreme inflation and notching a fiscal surplus.
But even experts who agree Argentina's health care system needed reform say the cutbacks have been so deep and fast that they've hit like a tidal wave.
'In terms of the destruction of the state, we've never experienced anything like this, not even during the military dictatorship,' said Fabio Nuñez, ex-coordinator of the National Directorate for HIV, Hepatitis and Tuberculosis who was among hundreds fired from the agency.
Charged with leading prevention efforts and treatments for infectious diseases, the agency has lost 40% of its staff and 76% of its annual budget. Hospitals now face shortages of everything from virus testing supplies to medications to condoms.
The cuts have coincided with a surge in sexually transmitted infections. Last year HIV cases spiked by 20% and syphilis by 50%.
'They're avoiding the expense now but will pay for it later as people seek emergency care,' said Cristian Pizzuti, a 31-year-old with HIV who documented 103 cases of patients deprived of their daily antiretroviral pills for weeks at a time last year. Pizzuti said he recently received expired medication and suffered a severe allergic reaction after being switched to a cheaper drug.
Tuberculosis cases also climbed by 25% last year. TB clinics report delays in obtaining test results.
'As people go about their lives, waiting for results, they are spreading the disease to others,' said Dr. Santiago Jimenez, who treats HIV and TB patients in an impoverished Buenos Aires neighborhood. 'It's an epidemiological disaster.'
Hospitals under strainFree public hospitals have become flooded with Argentines who dropped their private insurance due to increased premiums or who lost their job — and with it, their social security plans funded through payroll contributions. Buenos Aires facilities reported a 20%-30% increase in demand in the first quarter of 2025 compared to the same period last year.
The strain was visible at the free public Rodolfo Rossi Hospital in La Plata last month, where crowds jostled in the outpatient clinic and long lines spilled from the pharmacy.
Pharmacists have reported drug shortages as mass layoffs caused administrative chaos and the government froze a program that provided basic medications to Argentine public health centers.
Silvana Mansilla, 43, spent half the day waiting to pick up her monthly supply of thyroid medication — which has doubled in price to $22 — only to find the hospital had run out. 'Where's the government? What are they doing about this?' she asked.
With hiring frozen, doctors said they're handling double the patient load.
Overwhelmed by ever-increasing workloads, Argentina's leading public Garrahan Pediatric Hospital in Buenos Aires has hemorrhaged 200 medical professionals since Milei took office.
As annual inflation neared 200% last fall, their salaries lost half of their purchasing power. Doctors left for jobs abroad or better-paying work in private clinics. None were replaced. Medical residents ran a weeklong strike in May, displaying their pay slips for a month of 70-hour work weeks: $700.
Waiting for treatment A lawsuit filed by patient advocacy groups said more than 60 cancer patients have died due to the government's suspension of the DADSE medication program, and over 1,500 patients were waiting for their drugs.
A federal judge ordered the government to reinstate the drug deliveries, but it appealed, arguing that DADSE no longer exists. It said it had created a new, more efficient program to fulfill outstanding requests. But the timeline varies and sometimes the drugs don't come at all.
Timing was everything for patients like Alexis Almirón.
His medical records show the government drug bank received his request for an expensive medication to shrink his malignant tumor on Dec. 11, 2023, the day after Milei's inauguration. His doctor told the agency immediate treatment was urgently needed for the aggressive cancer.
Months passed. His mother, Claudia Caballero, bombarded DADSE with desperate calls asking what was taking so long as Almirón's lymphoma spread from his neck to his brain and stomach. He vomited blood. He lost his eyesight. Caballero tried to crowd-source the $20,000 for a month's supply of the drug but couldn't raise enough.
On March 12 last year, Almirón died at 22.
'They didn't give him the chance to choose to live,' Caballero said, her voice breaking.
The day after she buried her son, Caballero received a call from the Health Ministry. They had good news, the caller said: Her son's medication had finally arrived.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Plans unveiled for NHS funding to be linked to patient feedback
Plans unveiled for NHS funding to be linked to patient feedback

Yahoo

time7 minutes ago

  • Yahoo

Plans unveiled for NHS funding to be linked to patient feedback

NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Read more from Sky News Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph. "The ward clerk only works nine to five, or they're busy doing other stuff; the GP practice scrambles every morning."

Body fat predicts major health risk that BMI misses, researchers say
Body fat predicts major health risk that BMI misses, researchers say

Fox News

time27 minutes ago

  • Fox News

Body fat predicts major health risk that BMI misses, researchers say

Body mass index (BMI) may not be the most accurate predictor of death risk. A new study from the University of Florida found that BMI — a measurement that is commonly used to determine whether a person's weight is in a healthy range for their height — is "deeply flawed" in terms of predicting mortality. Instead, one's level of body fat is "far more accurate," concluded the study, which was published this week in the Annals of Family Medicine. To measure participants' body fat, the researchers used a method called bioelectrical impedance analysis (BIA), which uses a device to measure the resistance of body tissue to a small electrical current. Over a 15-year period, those who had high body fat were found to be 78% more likely to die than those who had healthy body fat levels, researchers found. They were also more than three times as likely to die of heart disease, the study noted. BMI — which is calculated by dividing weight by height, squared — was described as "entirely unreliable" in predicting the risk of death over a 15-year period from any cause. The study included 4,252 people in the U.S. and pulled data from the National Health and Nutrition Examination Survey. BMI should not be relied upon as a "vital sign" of health, according to senior author Frank Orlando, M.D., medical director of UF Health Family Medicine in Springhill. "I'm a family physician, and on a regular basis, we're faced with patients who have diabetes, heart disease, obesity and other conditions that are related to obesity," Orlando said in a press release for the study. "One of the routine measures we take alongside traditional vital signs is BMI. We use BMI to screen for a person having an issue with their body composition, but it's not as accurate for everyone as vital signs are," he added. BMI has been the international standard for measuring obesity since the 1980s, according to many sources, though some experts have questioned its validity. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." An individual is considered obese if their BMI is 30 or above, overweight if it is between 25 and 29.9, of "normal" weight in the range of 18.5 to 24.9, or underweight if lower than 18.5. While BMI is easy to calculate, one of its main limitations is that it cannot distinguish between muscle and fat mass, the researchers noted. "For example, people who are bodybuilders can really elevate their body mass index," Orlando said. "But they're healthy even with a BMI indicating that they're obese." "BMI is just so ingrained in how we think about body fat," Mainous added. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." Other methods, such as a DEXA (dual-energy X-ray absorptiometry) scan, may be even more accurate than BIA, but are much more expensive and not as accessible, the researchers noted. "If you talk to obesity researchers, they're going to say you have to use the DEXA scan because it's the most accurate," Mainous said in the release. "And that's probably true. But it's never going to be viable in a doctor's office or family practice." Dr. Stephen Vogel — a family medicine physician with PlushCare, a virtual health platform with primary care, therapy and weight management options — echoed the limitations of BMI. "It has been an easy measurement tool that helps us understand at-risk groups across various populations and demographics, but it doesn't provide accurate data from patient to patient," the North Carolina-based doctor, who was not involved in the study, told Fox News Digital. "These findings don't challenge the assumptions about BMI — they strengthen the message that new standards, delivered in a consistent and low-cost way, would provide better nuance for the individual when it comes to their overall physical health." "The main strengths of this study are a better correlation to an individual's risk of morbidity and mortality — however, the limitations lie in the fact that we don't have enough data to determine the right cutoff for these numbers, or to identify the right tools that will be both accurate and precise across the population," Vogel said. The researchers also acknowledged that body fat percentage thresholds haven't yet been as standardized as BMI and waist circumference. Also, the age range of the participants in the study was limited by the data source. "Future studies should extend this comparison of body fat to BMI in older adults," the researchers wrote. The study was also limited by focusing only on mortality as an outcome, they noted, without taking into account any developing diseases — such as heart failure or cancer — that could deepen the understanding of body fat as a risk factor. The goal, according to Vogel, is to have a cost-effective, consistent method that can be used across the population with reliable accuracy. "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all." "Benefits would come in the form of a more detailed list of information that helps providers and patients make informed decisions about the patient's health, which is ideal," Vogel noted. "I'm hopeful there's enough buzz around these measures that steps will continue to be taken toward regular implementation." For more Health articles, visit The researchers are hopeful that once standards are validated, measuring body fat percentage with bioelectrical impedance analysis could become standard of care. They added, "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all."

Citi Expresses Optimism for Eli Lilly and Company (LLY)
Citi Expresses Optimism for Eli Lilly and Company (LLY)

Yahoo

time31 minutes ago

  • Yahoo

Citi Expresses Optimism for Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store